

Information on PDMR transaction in PAXMAN AB (publ)

PAXMAN AB (publ) ("PAXMAN" or the "Company") announces that the Company's shareholder Björn Littorin has sold 300,000 shares in the Company. The acquiror has agreed to not divest any of the acquired shares, subject to customary exceptions, for a period of 180 days from 21 December 2021[1].

Following the transaction, Björn Littorin owns 465,076 shares in the Company and has agreed to not divest any additional shares, subject to customary exceptions, for period of 180 days from 21 December 2021[1].

[1] In connection with the directed share issue carried out by Paxman in 16 December 2021, Björn Littorin entered into a lock-up undertaking of 180 days from the settlement date on future divestments of shares in the Company, subject to certain conditions. The acquiror of Björn Littorin's shares has overtaken Björn Littorin's lock-up undertaking with regards to the acquired shares.

Contacts

Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

Information on PDMR transaction in PAXMAN AB (publ)